AU2001284792A1 - Augmented cognitive training - Google Patents

Augmented cognitive training

Info

Publication number
AU2001284792A1
AU2001284792A1 AU2001284792A AU8479201A AU2001284792A1 AU 2001284792 A1 AU2001284792 A1 AU 2001284792A1 AU 2001284792 A AU2001284792 A AU 2001284792A AU 8479201 A AU8479201 A AU 8479201A AU 2001284792 A1 AU2001284792 A1 AU 2001284792A1
Authority
AU
Australia
Prior art keywords
methods
cognitive training
cognitive
neuronal activity
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284792A
Inventor
Filippo Cavalieri
Timothy P. Tully
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of AU2001284792A1 publication Critical patent/AU2001284792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Business, Economics & Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Theoretical Computer Science (AREA)
  • Educational Administration (AREA)
  • Physics & Mathematics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • General Physics & Mathematics (AREA)
  • Educational Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Toys (AREA)
  • Control Of Eletrric Generators (AREA)

Abstract

The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.
AU2001284792A 2000-08-10 2001-08-10 Augmented cognitive training Abandoned AU2001284792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22422700P 2000-08-10 2000-08-10
US60/224,227 2000-08-10
PCT/US2001/025048 WO2002013867A2 (en) 2000-08-10 2001-08-10 Augmented cognitive training

Publications (1)

Publication Number Publication Date
AU2001284792A1 true AU2001284792A1 (en) 2002-02-25

Family

ID=22839775

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284792A Abandoned AU2001284792A1 (en) 2000-08-10 2001-08-10 Augmented cognitive training

Country Status (8)

Country Link
US (6) US7947731B2 (en)
EP (3) EP2316531A1 (en)
AT (1) ATE526020T1 (en)
AU (1) AU2001284792A1 (en)
DK (1) DK1355669T3 (en)
ES (1) ES2373540T3 (en)
PT (1) PT1355669E (en)
WO (1) WO2002013867A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
AU2001284792A1 (en) 2000-08-10 2002-02-25 Cold Spring Harbor Laboratory Augmented cognitive training
AU2003210447B2 (en) * 2002-01-04 2008-02-07 Henry Ford Health System Nitric oxide donors for treatment of disease and injury
DE60332029D1 (en) 2002-08-19 2010-05-20 Helicon Therapeutics Inc SCREENING PROCESS FOR COGNITIVE EXPANSION DEVICES
EP1540335B1 (en) * 2002-08-19 2010-04-07 Helicon Therapeutics, Inc. Screening methods for cognitive enhancers
US7725192B2 (en) * 2005-10-12 2010-05-25 The General Hospital Corporation Methods of increasing learning rate
EP2377533A3 (en) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
JP5016117B2 (en) 2008-01-17 2012-09-05 アーティキュレイト テクノロジーズ インコーポレーティッド Method and apparatus for intraoral tactile feedback
US9990859B2 (en) 2008-01-17 2018-06-05 Speech Buddies, Inc. Intraoral tactile biofeedback methods, devices and systems for speech and language training
EP2313098A4 (en) * 2008-07-18 2011-12-21 Dart Neuroscience Llc Methods and systems for evaluating memory agents
DK3489238T3 (en) 2012-06-18 2022-01-10 Dart Neuroscience Llc PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO [3,2-E] [1,2,4] TRIAZOLO [1,5-C] PYRIMIDIN-5-ON- AND [1,2,4] TRIAZOLO [1,5-C] PTERIDIN-5 (6H) -ON DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF EXAMPLE NEUROLOGICAL DISORDERS
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
BR112015022474B1 (en) 2013-03-14 2022-12-27 Dart Neuroscience (Cayman) Ltd PYRIDINE AND PYRAZINE COMPOUNDS SUBSTITUTED AS PDE4 INHIBITORS
AU2014241759B2 (en) 2013-03-14 2017-10-19 Dart Neuroscience (Cayman) Ltd. Substituted naphthyridine and quinoline compounds as MAO inhibitors
PL3597649T3 (en) 2014-04-23 2022-04-04 Dart Neuroscience Llc Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
MA39888A (en) 2014-04-24 2017-03-01 Dart Neuroscience Cayman Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c] pyridine compounds as glyt1 inhibitors
AU2015317638A1 (en) * 2014-09-17 2017-03-23 Dart Neuroscience (Cayman) Ltd. Mao-B inhibitors and rehabilitation
TWI601712B (en) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 Substituted azetidinyl compounds as glyt1 inhibitors
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
WO2016179434A1 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Systems and methods for cognitive testing
CN110337437B (en) 2016-12-28 2023-02-03 达特神经科学有限公司 Substituted pyrazolopyrimidinones as PDE2 inhibitors
KR102640696B1 (en) 2017-07-12 2024-02-27 다트 뉴로사이언스, 엘엘씨 Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
JP7254078B2 (en) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Substituted furanopyrimidine compounds as PDE1 inhibitors
JP7386797B2 (en) 2018-02-28 2023-11-27 ダート・ニューロサイエンス・エルエルシー Substituted cyclohexyl compounds as NOP inhibitors
GB201911024D0 (en) * 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
EP4252750A1 (en) 2022-03-31 2023-10-04 Leibniz-Institut für Neurobiologie Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686225A (en) * 1986-04-29 1987-08-11 American Home Products Corporation (Del.) Vinpocetine for pulmonary hemorrhage and edema
KR920702606A (en) 1989-06-13 1992-10-06 스튜어트 알. 슈터 Inhibition of Monokines
KR920702621A (en) 1989-06-13 1992-10-06 스튜어트 알. 슈터 Inhibition of Interleukin-1 or Tumor Factor Factor Production by Monocytes and / or Macrophages
JP2578001B2 (en) * 1989-12-11 1997-02-05 明治製菓株式会社 Anti-dementia drug
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
US5681735A (en) 1992-04-10 1997-10-28 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
DE4310699A1 (en) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
EP0781335A1 (en) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
HUP9801155A3 (en) * 1995-02-15 1999-03-01 Richter Gedeon Vegyeszet Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein
ES2097703B1 (en) * 1995-04-12 1997-12-01 Decox S L A NEW STIMULATING COMPOSITION OF BRAIN ACTIVITY BASED ON EBURNAMENINE NUCLEUS ALKALOIDS, AND ITS PREPARATION METHODS.
US5882203A (en) * 1995-05-31 1999-03-16 Correa; Elsa I. Method of detecting depression
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
DK0936923T3 (en) 1996-11-15 2004-04-26 Kennedy Inst Of Rheumatology Suppression of TNFalpha and IL-12 by therapy
US6258794B1 (en) * 1999-12-14 2001-07-10 The Mclean Hospital Corporation Treatment of mental conditions including depression
US6270077B1 (en) * 1999-12-20 2001-08-07 Gene D. Cohen Non-competitive memory enhancement game
AU2001284792A1 (en) 2000-08-10 2002-02-25 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20040053810A1 (en) 2002-08-16 2004-03-18 Tully Jo Anne Liquid laundry compositions comprising silicone additives
DE60332029D1 (en) 2002-08-19 2010-05-20 Helicon Therapeutics Inc SCREENING PROCESS FOR COGNITIVE EXPANSION DEVICES
EP2377533A3 (en) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
DK3489238T3 (en) * 2012-06-18 2022-01-10 Dart Neuroscience Llc PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO [3,2-E] [1,2,4] TRIAZOLO [1,5-C] PYRIMIDIN-5-ON- AND [1,2,4] TRIAZOLO [1,5-C] PTERIDIN-5 (6H) -ON DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF EXAMPLE NEUROLOGICAL DISORDERS

Also Published As

Publication number Publication date
WO2002013867A2 (en) 2002-02-21
US8455538B2 (en) 2013-06-04
DK1355669T3 (en) 2011-11-21
US20110224287A1 (en) 2011-09-15
ES2373540T3 (en) 2012-02-06
EP1355669A2 (en) 2003-10-29
US7947731B2 (en) 2011-05-24
EP2316531A1 (en) 2011-05-04
US20130164721A1 (en) 2013-06-27
ATE526020T1 (en) 2011-10-15
EP1355669B1 (en) 2011-09-28
US20130274704A1 (en) 2013-10-17
US20110224146A1 (en) 2011-09-15
EP2305353A1 (en) 2011-04-06
US20020076398A1 (en) 2002-06-20
WO2002013867A3 (en) 2003-08-07
US20150141441A1 (en) 2015-05-21
PT1355669E (en) 2012-01-02

Similar Documents

Publication Publication Date Title
AU2001284792A1 (en) Augmented cognitive training
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
EP1990338A3 (en) Biphenylcyclopropylamides as p-38 Kinase inhibitors
WO2002098890A3 (en) MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
PL373626A1 (en) Treatment for central nervous system disorders
WO2004036370A3 (en) Channel-selective blanking for a medical device system
GB2333453A (en) Colostrinin and uses thereof
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
IL150548A0 (en) Brain, spinal and nerve injury treatment
WO2002098356A3 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
AU4331400A (en) Neurotrophic substituted pyrimidines
EP1471871A4 (en) Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO2003014300A3 (en) TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2020080865A3 (en) Magnetic field stimulator-equipped massage device and method for preventing and treating brain disorders such as dementia or depression
AU1447095A (en) Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
WO2003006614A3 (en) UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005010148A3 (en) Marks as modifiers of the pten pathway and methods of use
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1406605A4 (en) Carbamates of 2-heterocyclic-1,2-ethanediols
WO2004058154A3 (en) Method of identifying therapeutic agents
EP1438432A4 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2003045314A3 (en) Mhyps as modifiers of branching morphogenesis and methods of use